Denovicon Therapeutics

The traditional approach to bring medicines to market is a slow and expensive process, costing upward of $1bn and often a decade or more of research. For all the effort it requires, only a small fraction (~14%) of drug candidates will ever achieve market approval. This industry needs a revolution. 

Denovicon's mission is to bring better quality drugs to market faster and more affordably than existing methods. To do so, they've created a drug discovery platform that's powered by AI, machine learning, generative therapeutic design, and physics-based approaches to achieve the best results.

The platform effectively and swiftly triages billions upon billions of molecules to identify high-quality leads and transform them into optimized clinical candidates. In this way, the platform streamlines the overall drug discovery process leading to savings in time and money, while achieving higher rates of clinical success – and down the line, to better patient outcomes.  

Denovicon supports the UN Sustainable Development Goal 3: Good Health and Well-Being by accelerating the development of life-saving medicines for some of the world’s most serious diseases, including heart disease and cancer.

In 2019, heart disease was responsible for 33% of all deaths worldwide, while cancer accounted for 18%. Unfortunately, the long timeline and high failure rate of traditional drug discovery means many patients are left waiting for new medicines to arrive for these and many other diseases. By dramatically shortening the timeline and cutting associated costs while ensuring higher clinical success, Denovicon is increasing the number of high-quality medicines that are more readily and affordably available for patients.

Denovicon leverages BIOVIA software to continuously enhance and extend the capabilities of its own platform. The company uses Pipeline Pilot to create advanced custom workflows and for integration; Discovery Studio for physics-based small-molecule modeling; and Generative Therapeutic Design for multi-property optimization.

As a member of the Lab, Denovicon benefits greatly from being exposed to a vast network of academic and research organizations, as well as other start-ups in the biotech and pharma space. While already an established member of the drug discovery industry, the company stands to gain valuable insights from the partnerships and mentorship opportunities the 3DEXPERIENCE lab offers.